Patents by Inventor Joseph Carr

Joseph Carr has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Humanized antibodies to cluster of differentiation 3 (CD3)
    Patent number: 10000567
    Abstract: Humanized monoclonal antibodies (mAbs) or fragments thereof, to human Cluster of Differentiation 3 (CD3), which confer improved immune stimulation and stability, are disclosed. Pharmaceutical compositions comprising said mAbs and methods of treatment and optionally also prevention of diseases and disorders, such as autoimmune disorders, infectious diseases, and transplant rejection, that are susceptible to amelioration by binding to CD3, are also disclosed.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: June 19, 2018
    Assignee: Therapix Biosciences Ltd.
    Inventors: Ronald Ellis, Michael Tal, Sarit Samira, Nurit Rachamim, Timothy David Jones, Francis Joseph Carr, Shahar Dotan
  • Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity
    Patent number: 9988444
    Abstract: The invention relates to polypeptides that comprise a portion of filamentous bacteriophage gene 3 protein (g3p) sufficient to bind to and/or disaggregate amyloid, e.g., the N1-N2 portion of g3p and mutants and fragments thereof, wherein that g3p amino acid sequence has been modified through amino acid substitution to be substantially less immunogenic than the corresponding wild-type g3p amino acid sequence when used in vivo. The polypeptides of the invention retain their ability bind to and/or disaggregate amyloid. The invention relates furthermore to the use of these variant g3p-polypeptides in the treatment and/or prevention of diseases associated with misfolding or aggregation of amyloid.
    Type: Grant
    Filed: May 28, 2014
    Date of Patent: June 5, 2018
    Assignee: PROCLARA BIOSCIENCES, INC.
    Inventors: Richard A. Fisher, Robert George Edward Holgate, Francis Joseph Carr, Timothy David Jones
  • Ribotoxin molecules derived from sarcin and other related fungal ribotoxins
    Patent number: 9976131
    Abstract: The present application relates to modified T cell epitopes derived from fungal ribotoxins, including ?-sarcin, clavin, gigantin, mitogillin, and restrictocin, as well as modified ribotoxin molecules comprising one or more of the modified epitopes. The modified ribotoxin molecules inhibit protein synthesis, like the wild type ribotoxins, but exhibit reduced immunogenicity as compared to the corresponding wild type ribotoxin. Another aspect relates to a fusion protein which comprises a modified ribotoxin fused or conjugated or otherwise linked to a targeting molecule that is effective for binding a target of interest. Another aspect relates to the use of the modified ribotoxin or fusion protein for treating or managing a disease or condition.
    Type: Grant
    Filed: February 13, 2017
    Date of Patent: May 22, 2018
    Assignee: RESEARCH CORPORATION TECHNOLOGIES, INC.
    Inventors: Kurt R. Gehlsen, Timothy David Jones, Francis Joseph Carr, Arron Hearn
  • PRINTABLE DEVICE WAFERS WITH SACRIFICIAL LAYERS
    Publication number: 20180130829
    Abstract: Methods of forming integrated circuit devices include forming a sacrificial layer on a handling substrate and forming a semiconductor active layer on the sacrificial layer. The semiconductor active layer and the sacrificial layer may be selectively etched in sequence to define an semiconductor-on-insulator (SOI) substrate, which includes a first portion of the semiconductor active layer. A multi-layer electrical interconnect network may be formed on the SOI substrate. This multi-layer electrical interconnect network may be encapsulated by an inorganic capping layer that contacts an upper surface of the first portion of the semiconductor active layer. The capping layer and the first portion of the semiconductor active layer may be selectively etched to thereby expose the sacrificial layer.
    Type: Application
    Filed: January 8, 2018
    Publication date: May 10, 2018
    Inventors: Christopher Bower, Etienne Menard, Matthew Meitl, Joseph Carr
  • DC output wind turbine with power dissipation
    Patent number: 9945359
    Abstract: A wind turbine is disclosed having a generator and rectifier and structured to provide direct current power that in one form is medium voltage direct current (MVDC). The wind turbine includes a crowbar circuit arranged to protect from a condition such as an overvoltage. The crowbar can be activated based on a voltage measurement or rate of change of voltage. A resistor can be coupled to the crowbar to absorb excess power provided by the generator during the overvoltage condition. Individual wind turbines in a wind farm can each have individual crow bars that can be activated based on local measurement of a voltage condition. In some forms the crowbar can be coupled with a transformer, for example coupled with a tertiary winding of a three winding transformer.
    Type: Grant
    Filed: August 13, 2015
    Date of Patent: April 17, 2018
    Assignee: ABB Schweiz AG
    Inventors: Debrup Das, Jiuping Pan, Joseph A. Carr
  • Humanized antibodies to iNKT
    Patent number: 9932402
    Abstract: Methods of treatment to suppress an immune response are provided. The method comprises administering to a subject in need of treatment a naked blocking antibody that binds selectively iNKT cells in an amount effective to suppress the subject's iNKT cell function. Compositions comprising, an isolated, humanized antibody that binds selectively iNKT cells are also provided.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: April 3, 2018
    Assignee: NKT Therapeutics Inc.
    Inventors: Alemseged Truneh, Francis Joseph Carr, Timothy David Jones, James P. Gregson
  • Anti-MET Antibodies and Methods of Use Thereof
    Publication number: 20180057595
    Abstract: Provided herein are compositions, methods and uses involving antibodies that specifically bind to MET, a receptor tyrosine kinase, and modulate the expression and/or activity of MET. Also provided are uses and methods for managing, treating, or preventing disorders, such as cancer. In one aspect, provided herein is a monoclonal antibody or antigen-binding fragment thereof that binds to the Sema/PSI domain of human MET. Also provided herein is a kit comprising an antibody or antigen-binding fragment provided herein. Also provided herein is a method of managing, protecting against, or treating cancer in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of an antibody or antigen-binding fragment provided herein.
    Type: Application
    Filed: March 15, 2016
    Publication date: March 1, 2018
    Applicant: Celldex Therapeutics, Inc.
    Inventors: Yan Yang, Sreekala Mandiyan, Brett Robinson, Lida Kimmel, Yaron Hadari, Timothy David Jones, Francis Joseph Carr, Robert George Edward Holgate, Richard Weldon
  • Printable device wafers with sacrificial layers gaps
    Patent number: 9899432
    Abstract: Methods of forming integrated circuit devices include forming a sacrificial layer on a handling substrate and forming a semiconductor active layer on the sacrificial layer. The semiconductor active layer and the sacrificial layer may be selectively etched in sequence to define an semiconductor-on-insulator (SOI) substrate, which includes a first portion of the semiconductor active layer. A multi-layer electrical interconnect network may be formed on the SOI substrate. This multi-layer electrical interconnect network may be encapsulated by an inorganic capping layer that contacts an upper surface of the first portion of the semiconductor active layer. The capping layer and the first portion of the semiconductor active layer may be selectively etched to thereby expose the sacrificial layer.
    Type: Grant
    Filed: August 22, 2016
    Date of Patent: February 20, 2018
    Assignee: X-Celeprint Limited
    Inventors: Christopher Bower, Etienne Menard, Matthew Meitl, Joseph Carr
  • Methods and compositions with immune therapy for treatment of dementia
    Patent number: 9879076
    Abstract: Novel antibodies, methods and compositions for treatment of a disease which is susceptible to amelioration by the blocking of APP cleavage.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: January 30, 2018
    Assignee: RAMOT AT TEL AVIV UNIVERSITY LTD.
    Inventors: Sarit Samira, Nurit Rachamim, Michael Tal, Ronald Ellis, Idan Rakover, Rom E. Eliaz, Beka Solomon, Timothy David Jones, Francis Joseph Carr, Polina Rabinovich-Toidman, Meital Sooliman
  • MODIFIED FORMS OF PSEUDOMONAS EXOTOXIN A
    Publication number: 20170275600
    Abstract: Pseudomonas exotoxin A or “PE” is a 66 kD, highly potent, cytotoxic protein secreted by the bacterium Pseudomonas aeruginosa. Various forms of PE have been coupled to other proteins, such as antibodies, to generate therapeutically useful cytotoxin conjugates that selectively target cells of a desired phenotype (such as tumor cells). In the present invention, peptides spanning the sequence of an approximately 38 kD form of Pseudomonas exotoxin A protein were analyzed for the presence of immunogenic CD4+ T cell epitopes. Six immunogenic T cell epitopes were identified. Residues were identified within each epitope for introduction of targeted amino acid substitutions to reduce or prevent immunogenic T-cell responses in PE molecules which may be administered to a heterologous host.
    Type: Application
    Filed: April 6, 2017
    Publication date: September 28, 2017
    Applicant: Intrexon Corporation
    Inventors: Timothy David Jones, Francis Joseph Carr
  • PRESSURE-SENSITIVE ADHESIVES INCLUDING EXPANDABLE GRAPHITE
    Publication number: 20170275500
    Abstract: A building material comprising a substrate layer and a pressure-sensitive adhesive layer, where the pressure-sensitive adhesive layer includes expandable graphite.
    Type: Application
    Filed: June 12, 2017
    Publication date: September 28, 2017
    Inventors: Wensheng ZHOU, Michael J. HUBBARD, Joseph CARR
  • PRESSURE-SENSITIVE ADHESIVES INCLUDING EXPANDABLE GRAPHITE
    Publication number: 20170267896
    Abstract: A building material comprising a substrate layer and a pressure-sensitive adhesive layer, where the pressure-sensitive adhesive layer includes expandable graphite.
    Type: Application
    Filed: June 5, 2017
    Publication date: September 21, 2017
    Inventors: Wensheng ZHOU, Michael J. HUBBARD, Joseph CARR
  • Hybrid alternating current (AC)/direct current (DC) distribution for multiple-floor buildings
    Patent number: 9755433
    Abstract: A hybrid alternating current (AC)/direct current (DC) distribution system for multiple-floor buildings includes per-floor rectifiers for converting supply side AC to DC. Each rectifier is configured to supply a plurality of DC loads associated with one floor of a multiple-floor building. The system further includes per-floor DC busses, each of the DC busses being configured to distribute the DC to the DC loads its respective floor. The system further includes at least one AC bus for supplying AC power to AC loads in the building.
    Type: Grant
    Filed: November 20, 2013
    Date of Patent: September 5, 2017
    Assignee: ABB Schweiz AG
    Inventors: Jing Xu, Zhenyuan Wang, Waqas Arshad, Joseph A. Carr
  • Humanised anti CTLA-4 antibodies
    Patent number: 9714290
    Abstract: The invention provides an anti-CTLA4 antibody which inhibits the binding of CTLA4 to human B7, in particular, it inhibits binding of CTLA4 to human B7.1 and/or human B7.2. Specific antibodies are provided with specific variable region sequences as well as compositions comprising such antibodies for use in treating disease.
    Type: Grant
    Filed: March 9, 2012
    Date of Patent: July 25, 2017
    Assignee: ANTITOPE LIMITED
    Inventors: Timothy David Jones, Robert George Edward Holgate, Francis Joseph Carr
  • RIBOTOXIN MOLECULES DERIVED FROM SARCIN AND OTHER RELATED FUNGAL RIBOTOXINS
    Publication number: 20170204387
    Abstract: The present application relates to modified T cell epitopes derived from fungal ribotoxins, including ?-sarcin, clavin, gigantin, mitogillin, and restrictocin, as well as modified ribotoxin molecules comprising one or more of the modified epitopes. The modified ribotoxin molecules inhibit protein synthesis, like the wild type ribotoxins, but exhibit reduced immunogenicity as compared to the corresponding wild type ribotoxin. Another aspect relates to a fusion protein which comprises a modified ribotoxin fused or conjugated or otherwise linked to a targeting molecule that is effective for binding a target of interest. Another aspect relates to the use of the modified ribotoxin or fusion protein for treating or managing a disease or condition.
    Type: Application
    Filed: February 13, 2017
    Publication date: July 20, 2017
    Inventors: Kurt R. Gehlsen, Timothy David Jones, Francis Joseph Carr, Arron Hearn
  • ROOFING MEMBRANES WITH EXPANDABLE GRAPHITE AS FLAME RETARDANT
    Publication number: 20170191271
    Abstract: A roofing membrane comprising at least one layer of a cured rubber and expandable graphite dispersed within the cured rubber.
    Type: Application
    Filed: March 22, 2017
    Publication date: July 6, 2017
    Applicant: FIRESTONE BUILDING PRODUCTS CO., LLC
    Inventors: Hao WANG, Wensheng ZHOU, Joseph CARR
  • Pressure-sensitive adhesives including expandable graphite
    Patent number: 9688887
    Abstract: A building material comprising a substrate layer and a pressure-sensitive adhesive layer, where the pressure-sensitive adhesive layer includes expandable graphite.
    Type: Grant
    Filed: February 6, 2015
    Date of Patent: June 27, 2017
    Assignee: Firestone Building Products Co., LLC
    Inventors: Wensheng Zhou, Michael J. Hubbard, Joseph Carr
  • Pressure-sensitive adhesives including expandable graphite
    Patent number: 9683135
    Abstract: A building material comprising a substrate layer and a pressure-sensitive adhesive layer, where the pressure-sensitive adhesive layer includes expandable graphite.
    Type: Grant
    Filed: November 7, 2013
    Date of Patent: June 20, 2017
    Assignee: FIRESTONE BUILDING PRODUCTS CO., LLC
    Inventors: Wensheng Zhou, Michael J. Hubbard, Joseph Carr
  • Modified forms of exotoxin A
    Patent number: 9677055
    Abstract: Pseudomonas exotoxin A or “PE” is a 66 kD, highly potent, cytotoxic protein secreted by the bacterium Pseudomonas aeruginosa. Various forms of PE have been coupled to other proteins, such as antibodies, to generate therapeutically useful cytotoxin conjugates that selectively target cells of a desired phenotype (such as tumor cells). In the present invention, peptides spanning the sequence of an approximately 38 kD form of Pseudomonas exotoxin A protein were analyzed for the presence of immunogenic CD4+ T cell epitopes. Six immunogenic T cell epitopes were identified. Residues were identified within each epitope for introduction of targeted amino acid substitutions to reduce or prevent immunogenic T-cell responses in PE molecules which may be administered to a heterologous host.
    Type: Grant
    Filed: August 11, 2016
    Date of Patent: June 13, 2017
    Assignee: Interxon Corporation
    Inventors: Timothy David Jones, Francis Joseph Carr
  • ANTI-KIT ANTIBODIES AND USES THEREOF
    Publication number: 20170158778
    Abstract: Provided herein, in one aspect, are antibodies that immunospecifically bind to a human KIT antigen comprising the fourth and/or fifth extracellular Ig-like domains (that is, D4 and/or D5 domains), polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies. The antibodies can inhibit KIT activity, such as ligand-induced receptor phosphorylation. Also provided herein are kits and pharmaceutical compositions comprising antibodies that specifically bind to a KIT antigen, as well as methods of treating or managing a KIT-associated disorder or disease and methods of diagnosing a KIT-associated disorder or disease using the antibodies described herein.
    Type: Application
    Filed: February 15, 2017
    Publication date: June 8, 2017
    Applicant: CELLDEX THERAPEUTICS, INC.
    Inventors: Yaron Hadari, Elizabeth M Mandel-Bausch, Francis Joseph Carr, Timothy David Jones, Laura Clare Alexandra Perry